Navigation Links
Regado Biosciences, Inc. Adds Global Pharmaceutical Business Veteran to Board of Directors
Date:11/18/2013

BASKING RIDGE, N.J., Nov. 18, 2013 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced the appointment of Pierre Legault, MBA, CA, CPA, to its Board of Directors, where he will serve as Chairman of the audit committee. 

Mr. Legault has extraordinarily broad executive management experience, including more than 30 years spent executing creative financing strategies, driving corporate development, and constructing value-driving transactions for international biotechnology and pharmaceutical companies.  In addition, Mr. Legault has significant experience serving on the board of directors and audit committees of public companies.

Mr. Legault is currently CEO of NephroGenex, a late-stage biotech company, and was previously Executive Chairman.  He is also President and CEO of Stone Management LLC, a firm focused in the areas of business development and board assistance.  From 2009 to 2012, he held leadership positions at Astellas Pharmaceuticals and its legacy companies, including Chief Executive Officer of Prosidion Ltd., and Executive VP, CFO and Treasurer of OSI Pharmaceuticals.  From January 2006 to December 2008, Mr. Legault worked for Rite Aid Corporation, a Fortune 500 publicly traded pharmaceutical retail company, most recently as senior executive vice president and chief administrative officer.  Prior to Rite Aid Corporation, Mr. Legault held several senior positions over 15+ years at Sanofi-Aventis and predecessor companies, serving most recently as Worldwide President of a large, global dermatology business unit.

In addition, Mr. Legault has served on several public, private and nonprofit company boards and audit committees, including Forest Laboratories, Inc., on which he serves currently as audit committee Chairman.  Prior board positions include OSI Investment Holdings GMBH (Chairman), Cyclacel Pharmaceutical Inc., PJC Inc., as well as other private boards.  Mr. Legault studied at the Harvard Business School in an executive masters program and he received his MBA from McGill University and his BAA from University of Montreal (HEC).  He also holds CA and CPA degrees.

Mr. Legault stated, "Throughout my career I have chosen board appointments very carefully, and I see a tremendous opportunity in Regado.  As the company continues to drive toward clinical success with REG1, I look forward to offering my expertise and guidance."

Dennis Podlesak, MBA, Regado's Board Chairman, stated, "We are very pleased to add Mr. Legault to our board of directors and as our audit committee Chairman.  We believe his specific expertise in this role will be a valuable asset for Regado, as will his impressive background in running international pharmaceutical companies across the full spectrum of clinical and commercial development." 

ABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc. is a biopharmaceutical company focused on the development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications.  Regado is pioneering the development of two-component drug systems consisting of a therapeutic aptamer and its specific active control agent. The company's lead product candidate, REG1, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen.  REG1 is being developed for use in patients with a wide variety of acute coronary syndromes, or ACS, undergoing a percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. Regado's actively controllable product candidates have the potential to improve patient outcomes, enhance the patient experience and reduce overall treatment costs.  More information can be found at www.regadobio.com.

For more information on REGULATE-PCI, please visit: 
http://www.clinicaltrials.gov/ct2/show/NCT01848106?term=Regado&rank=1

Contact: 
Tiberend Strategic Advisors, Inc.

Investors - Joshua Drumm, Ph.D. 
jdrumm@tiberend.com; (212) 375-2664

Media - Andrew Mielach 
amielach@tiberend.com; (212) 375-2694


'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regado Biosciences, Inc. Announces Third Quarter 2013 Results
2. Regado Biosciences, Inc. Announces Closing of Initial Public Offering
3. Regado Biosciences, Inc. Announces Pricing of Initial Public Offering
4. Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
5. Regado Biosciences, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York, NY
6. Regado Biosciences, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA
7. Regado Biosciences, Inc. to Present at the 2012 Wedbush PacGrow Life Sciences Conference in New York, NY
8. Pressure BioSciences, Inc. Discusses Record Third Quarter Revenue, Strong Fourth Quarter Guidance, Significant Progress on New Instrument Systems, and Expectation to Pay-Off All Outstanding Convertible Notes at the SeeThruEquity Financial Conference
9. Jeeven BioSciences, Inc. Announces the Release of its Neuro-X(TM) Serum Free and Xeno Free Tissue Culture Media
10. SeeThruEquity, LLC Initiates Coverage on Pressure BioSciences, Inc.
11. Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, ... a Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, ... winners, announced today online at www.diabetesscholars.org by ... 1 diabetes stand in the way of academic and ... the Foundation,s scholarship program since 2012, and continues to ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
Breaking Medicine News(10 mins):